Cowen and Company Reaffirms Hold Rating for ChemoCentryx, Inc. (CCXI)

ChemoCentryx, Inc. (NASDAQ:CCXI)‘s stock had its “hold” rating restated by Cowen and Company in a research report issued on Tuesday, August 8th.

The analysts wrote, “ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30.””

Separately, Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 17th.

Shares of ChemoCentryx (NASDAQ:CCXI) traded down 1.72% on Tuesday, reaching $6.87. The company had a trading volume of 141,943 shares. The company’s 50-day moving average price is $9.33 and its 200-day moving average price is $7.71. ChemoCentryx has a 52-week low of $4.17 and a 52-week high of $10.80. The firm’s market capitalization is $334.61 million.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. The business had revenue of $8.94 million during the quarter. On average, analysts predict that ChemoCentryx will post ($0.90) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Cowen and Company Reaffirms Hold Rating for ChemoCentryx, Inc. (CCXI)” was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/chemocentryx-inc-ccxi-receives-hold-rating-from-cowen-and-company-updated.html.

In other news, insider Petrus Bekker sold 30,000 shares of the company’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $9.98, for a total transaction of $299,400.00. Following the completion of the sale, the insider now directly owns 65,963 shares in the company, valued at approximately $658,310.74. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 223,649 shares of company stock valued at $2,157,360. Corporate insiders own 26.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. P.A.W. Capital Corp increased its stake in shares of ChemoCentryx by 33.3% in the first quarter. P.A.W. Capital Corp now owns 160,000 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 40,000 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of ChemoCentryx by 37.5% in the first quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock valued at $936,000 after buying an additional 35,049 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of ChemoCentryx during the first quarter valued at $1,050,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of ChemoCentryx during the first quarter valued at $189,000. Finally, Eagle Global Advisors LLC acquired a new stake in shares of ChemoCentryx during the first quarter valued at $337,000. Institutional investors and hedge funds own 49.37% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply